Mylan Inc (NASDAQ:MYL)

CAPS Rating: 4 out of 5

The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.

Results 1 - 20 of 99 : 1 2 3 4 5 Next »

Recs

0
Member Avatar TerryHoodSr (60.36) Submitted: 6/14/2014 10:04:52 AM : Outperform Start Price: $50.06 MYL Score: -6.43

SOLID LONGTERM BUY@50 TP 60

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 2/19/2014 4:50:54 PM : Underperform Start Price: $50.98 MYL Score: +14.18

Demark 13 weekly sell

Recs

0
Member Avatar BELLEXP (< 20) Submitted: 1/26/2014 7:17:58 AM : Outperform Start Price: $44.20 MYL Score: -2.14

EARNINGS OF NEW DRUGS COMING OFF PATENT

Recs

0
Member Avatar Zee (< 20) Submitted: 12/28/2013 8:05:01 PM : Outperform Start Price: $42.77 MYL Score: +4.47

strength in the emerging biotech market of biosimilars

Recs

0
Member Avatar DrLinks (53.88) Submitted: 7/24/2013 2:12:24 AM : Outperform Start Price: $32.32 MYL Score: +32.16

Mylan is a STRON generic s well as Proprietary drug maker!

Recs

0
Member Avatar BillZack (< 20) Submitted: 4/14/2013 1:23:36 PM : Underperform Start Price: $28.64 MYL Score: -42.66

Bearish head and shoulders pattern, too far too fast.

Recs

0
Member Avatar 10cent (97.07) Submitted: 3/21/2013 11:57:24 PM : Outperform Start Price: $30.34 MYL Score: +30.57

generic xanax

Recs

0
Member Avatar JorgeAura (23.06) Submitted: 2/2/2013 5:24:02 PM : Underperform Start Price: $28.81 MYL Score: -35.17

Nasdaq in maximums.

Recs

0
Member Avatar ArmchairTitan (43.80) Submitted: 3/2/2012 9:49:37 PM : Outperform Start Price: $23.15 MYL Score: +63.54

More generics means greater opportunity

Recs

0
Member Avatar XMFMT (95.92) Submitted: 1/3/2012 3:07:22 PM : Outperform Start Price: $18.85 MYL Score: +98.07

Second largest generic company world wide. Baby boomers need drugs, generics cheaper and with medical cuts this industry will benefit the most.

Recs

0
Member Avatar weartcw (< 20) Submitted: 8/12/2011 9:11:15 PM : Outperform Start Price: $19.39 MYL Score: +82.25

With almost 80% of all medications by prescrition dispensed last year as a generic and with 14 major Branded Medications scheduled to loose patent protection in the next year or so these companies are positioned to grow substantially.I believe that we will see price controls or considerable pressure for lower brand name prescription prices from our government and the PBMs inorder to allow branded medications preferred status on formularies much like most other nations. We have recently seen the UK NICE folks turn down Novartis's fingolimod for MS at a deep discount to the US cost about $30,000 per patient per year in the UK vs. over $50,000 per patient per year in the US. We do not have the rersources to continue to cover these high cost medications especially when the data is largely less than life changing. Patients and health care providers need to wake up and demand patient oriented outcome data that matters to patients from the pharmaceutical industry before we jump on the new expensive brand name meduication band wagon and continue to spend ourselves into debt. Generic medications are at least one step in the "Right" direction especially when we have compitition from multiple manufacturers. and as long as they are FDA approved and rated as generically equivalent I have no problem taking or recommending them.

Recs

0
Member Avatar stovkey1highdiv (< 20) Submitted: 4/14/2011 10:04:08 PM : Outperform Start Price: $23.32 MYL Score: +56.12

key03, no dividend

Recs

0
Member Avatar sirgenius (< 20) Submitted: 3/11/2011 6:22:59 PM : Outperform Start Price: $22.19 MYL Score: +64.61

Mylan makes generic drugs and the name brand companies are not investing in new drugs. 5, 6 or 7 years down the road more patents will expire and those drugs will go generic. People will want cheaper drugs in this economy. Mylan is building a new warehouse that is already 60% of capacity before the first wall went up.

Recs

0
Member Avatar poorbastard2011 (< 20) Submitted: 1/14/2011 7:22:43 AM : Outperform Start Price: $22.63 MYL Score: +58.19

the signs are there...

Recs

0
Member Avatar cashman79 (67.31) Submitted: 9/15/2010 9:55:36 AM : Outperform Start Price: $17.92 MYL Score: +92.64

watch

Recs

0
Member Avatar snakeflake (71.67) Submitted: 4/28/2010 8:54:13 AM : Outperform Start Price: $21.41 MYL Score: +58.40

Just got FDA approval to market generic versions of Flomax and Desoxin

Recs

0
Member Avatar pre92lude (< 20) Submitted: 3/9/2010 8:05:31 PM : Outperform Start Price: $21.68 MYL Score: +48.84

people buy generics...

Recs

0
Member Avatar zhilmi (< 20) Submitted: 1/28/2010 11:24:14 PM : Outperform Start Price: $18.01 MYL Score: +85.78

Generics, nice line of meds, improving stats

Recs

0
Member Avatar dutchredneck (81.51) Submitted: 9/23/2009 10:30:55 AM : Outperform Start Price: $16.11 MYL Score: +114.20

Growth stock will outperform the S&P.

Recs

0
Member Avatar 8tune (54.63) Submitted: 9/9/2009 1:46:27 PM : Outperform Start Price: $14.27 MYL Score: +146.33

Mylan generic pharma to outperform S&P.

Results 1 - 20 of 99 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement